A0A140VJC8 (A0A140VJC8_HUMAN) Homo sapiens (Human)
Amyloid-beta A4 protein UniProtKBInterProInteractive Modelling
770 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: P05067
It is possible new templates exist for this target since these models were created.
Available Structures
204 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Kunitz Protease … |
Heteromer P03951; P05067; | |||||
| Assess | ||||||
| RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN |
Heteromer P00763; P05067; | |||||
| Assess | ||||||
| Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human… |
Heteromer P05067; Q92876; | |||||
| Assess | ||||||
| Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human… |
Heteromer P05067; Q92876; | |||||
| Assess | ||||||
| BOVINE TRYPSIN COMPLEXED TO APPI |
Heteromer P00760; P05067; | 2×CA; | ||||
| Assess | ||||||
| BOVINE CHYMOTRYPSIN COMPLEXED TO APPI |
Heteromer P00766; P05067; | |||||
| Assess | ||||||
| Human mesotrypsin complexed with amyloid precursor protein inhibitor(APPI) |
Heteromer P05067; P35030; | 9×FMT; 1×CA; | ||||
| Assess | ||||||
| Structure of Human Mesotrypsin in complex with APPI variant T11V/M17R/I18F/F34V |
Heteromer P05067; P35030; | 1×EDO; | ||||
| Assess | ||||||
| Human Mesotrypsin in complex with amyloid precursor protein inhibitor variant APPI-M17G/I18F/F34V |
Heteromer P05067; P35030; | |||||
| Assess | ||||||
| Cryo-EM structure of the human formyl peptide receptor 2 in complex with Abeta42 and Gi2 |
Heteromer P04899; P05067; P25090; P59768; P62873; | |||||
| Assess | ||||||
| Recognition of the Amyloid Precursor Protein by Human gamma-secretase |
Heteromer P05067; P49768; Q92542; Q96BI3; Q9NZ42; | 5×NAG; 1×NAG; 6×NAG; 2×PC1; 3×CLR; | ||||
| Assess | ||||||
| Crystal structure of the intracellular domain of human APP in complex with Fe65-PTB2 |
Heteromer O00213; P05067; | |||||
| Assess | ||||||
| Crystal structure of the intracellular domain of human APP (T668A mutant) in complex with Fe65-PTB2 |
Heteromer O00213; P05067; | |||||
| Assess | ||||||
| Crystal structure of the intracellular domain of human APP (T668E mutant) in complex with Fe65-PTB2 |
Heteromer O00213; P05067; | |||||
| Assess | ||||||
| Structure of Alzheimer Ab peptide in complex with an engineered binding protein |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-40) |
Heteromer P05067; P14735; | 1×DIO; | ||||
| Assess | ||||||
| Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-42) |
Heteromer P05067; P14735; | 1×ZN; | ||||
| Assess | ||||||
| Crystal Structure Analysis of Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Amyloi… |
Heteromer P05067; P14735; | 1×ZN; | ||||
| Assess | ||||||
| ANTIBODY C706 IN COMPLEX WTH BETA-AMYLOID PEPTIDE 1-16 |
Heteromer P05067; | 4×SO4; 3×GOL; | ||||
| Assess | ||||||
| Fab-amyloid beta fragment complex at neutral pH |
Heteromer P05067; | 1×CL; 1×NA; | ||||
| Assess | ||||||
| Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide |
Heteromer P05067; | 1×EDO; 1×ZN; | ||||
| Assess | ||||||
| Fab-amyloid beta fragment complex |
Heteromer P05067; | 3×EDO; 2×PEG; | ||||
| Assess | ||||||
| Crystal structure of APP peptide bound rat Mint2 PARM |
Heteromer O35431; P05067; | |||||
| Assess | ||||||
| Crystal structure of an engineered lipocalin (Anticalin US7) in complex with the Alzheimer amyloid … |
Heteromer P05067; P80188; | |||||
| Assess | ||||||
| X11 PTB DOMAIN |
Heteromer P05067; Q02410; | |||||
| Assess | ||||||
| Structure of Pyroglutamate-Abeta-specific Fab c#24 in complex with human Abeta-pE3-18 |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal Structure of the GULP1 PTB domain-APP peptide complex |
Heteromer P05067; Q9UBP9; | 2×SO4; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of crenezumab Fab in complex with Abeta |
Heteromer P05067; P0DOX5; Q0KKI6; | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF GANTENERUMAB FAB FRAGMENT IN COMPLEX WITH ABETA 1-11 |
Heteromer P05067; | 1×NAG; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of an engineered lipocalin (Anticalin H1GA) in complex with the Alzheimer amyloid… |
Heteromer P05067; P80188; | |||||
| Assess | ||||||
| Crystal Structure of mid-region amyloid beta capture by solanezumab |
Heteromer P01834; P01857; P05067; | |||||
| Assess | ||||||
| Fab-antibody complex |
Heteromer P05067; | |||||
| Assess | ||||||
| 24B3 antibody-peptide complex |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal Structure of TAP01 in complex with amyloid beta peptide |
Heteromer P05067; | 1×FLC; | ||||
| Assess | ||||||
| Structure of Pyroglutamate-Abeta-specific Fab c#6 in complex with human Abeta-pE3-12-PEGb |
Heteromer P05067; | 1×SO4; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of MMP-2 active site mutant in complex with APP-drived decapeptide inhibitor |
Heteromer P05067; P08253; | 2×ZN; 3×CA; | ||||
| Assess | ||||||
| Crystal Structure of Human Presequence Protease in Complex with Amyloid-beta (1-40) |
Heteromer P05067; Q5JRX3; | 1×ZN; 1×GOL; 2×ACT; | ||||
| Assess | ||||||
| Design of a split green fluorescent protein for sensing and tracking an beta-amyloid |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal structure of the complex formed between Phospholipase A2 with beta-amyloid fragment, Lys-Gl… |
Heteromer P05067; P60045; | 1×CA; | ||||
| Assess | ||||||
| Phospholipase A2 Prevents the Aggregation of Amyloid Beta Peptides: Crystal Structure of the Comple… |
Heteromer P05067; P60045; | 1×CA; | ||||
| Assess | ||||||
| X-ray structure of amyloid beta peptide:antibody (Abeta1-7:12A11) complex |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal structure of Fab wo2 bound to the n terminal domain of amyloid beta peptide (1-16) |
Heteromer A2NHM3; P05067; P84751; | |||||
| Assess | ||||||
| Crystal structure of Fab WO2 bound to the N terminal domain of Amyloid beta peptide (1-28) |
Heteromer A2NHM3; P05067; Q811U5; | |||||
| Assess | ||||||
| Crystal structure of adaptor protein complex 4 (AP-4) mu4 subunit C-terminal domain, in complex wit… |
Heteromer O00189; P05067; | 3×GOL; | ||||
| Assess | ||||||
| PFA1 Fab fragment complexed with Abeta 1-8 peptide |
Heteromer A2NHM3; P05067; | 2×ACM; 3×GOL; | ||||
| Assess | ||||||
| Cereblon isoform 4 from Magnetospirillum gryphiswaldense in complex a long aspartimide degron pepti… |
Heteromer A4TVL0; P05067; | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of adaptor protein complex 4 (AP-4) mu4 subunit C-terminal domain D190A mutant, i… |
Heteromer O00189; P05067; | |||||
| Assess | ||||||
| Structures of Grb2-SH2 Domain and AICD peptide Complexes Reveal a Conformational Switch and Their F… |
Heteromer P05067; P62993; | |||||
| Assess | ||||||
| Crystal Structure of the Complex Formed Between a New Isoform of Phospholipase A2 with C-terminal A… |
Heteromer P05067; P60045; | 1×CA; | ||||
| Assess | ||||||
| Structures of Grb2-SH2 Domain and AICD peptide Complexes Reveal a Conformational Switch and Their F… |
Heteromer P05067; P62993; | |||||
| Assess | ||||||
| Crystal Structure of the VAV2 SH2 domain in complex with APP phosphorylated peptide |
Heteromer P05067; P52735; | |||||
| Assess | ||||||
| PFA2 FAB complexed with Abeta1-8 |
Heteromer A2NHM3; P05067; Q811U5; | 1×NA; | ||||
| Assess | ||||||
| Crystal Structure of the Complex Formed Between Phospholipase A2 and a Hexapeptide Fragment of Amyl… |
Heteromer P05067; P60045; | 1×CA; | ||||
| Assess | ||||||
| X-ray structure of amyloid beta peptide:antibody (Abeta1-40:12A11) complex |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal structure of an engineered lipocalin (Anticalin US7) in complex with the Alzheimer amyloid … |
Heteromer P05067; P80188; | |||||
| Assess | ||||||
| Humanised 3D6 Fab complexed to amyloid beta 1-8 |
Heteromer P05067; | |||||
| Assess | ||||||
| Fab fragment of 3D6 in complex with amyloid beta 1-7 |
Heteromer P05067; | |||||
| Assess | ||||||
| X-ray structure of amyloid beta peptide:antibody (Abeta1-7:10D5) complex |
Heteromer P05067; | |||||
| Assess | ||||||
| Crystal structure of a humanised 3D6 Fab bound to amyloid beta peptide |
Heteromer P01834; P01857; P05067; | |||||
| Assess | ||||||
| Structure of Pyroglutamate-Abeta-specific Fab c#17 in complex with human Abeta-pE3-12PEGb |
Heteromer P05067; | |||||
| Assess | ||||||
| aducanumab abeta complex |
Heteromer P05067; | 1×SO4; | ||||
| Assess | ||||||
| X-ray structure of amyloid beta peptide:antibody (Abeta1-7:12B4) complex |
Heteromer P05067; | |||||
| Assess | ||||||
| Alzheimer's Amyloid-Beta Peptide Fragment 29-40 in Complex with Cd-substituted Thermolysin |
Heteromer P05067; P43133; | 1×CA; 4×CD; 1×DMS; | ||||
| Assess | ||||||
| Alzheimer's Amyloid-Beta Peptide Fragment 1-40 in Complex with Cd-substituted Thermolysin |
Heteromer P05067; P43133; | 3×CA; 2×CD; 1×DMS; | ||||
| Assess | ||||||
| Fab fragment of 3D6 in complex with amyloid beta 1-40 |
Heteromer P05067; | 27×ZN; 3×IMD; 11×CL; | ||||
| Assess | ||||||
| Alzheimer's Amyloid-Beta Peptide Fragment 1-40 in Complex with Thermolysin |
Heteromer P00800; P05067; | 4×CA; 1×ZN; 1×DMS; | ||||
| Assess | ||||||
| Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 4-10 |
Heteromer P05067; P12821; | 1×NAG; 1×NAG; 1×NAG; 1×ZN; 1×CL; 1×SO4; 4×PEG; | ||||
| Assess | ||||||
| Structure of Human Neurolysin (E475Q) in complex with amyloid-beta 35-40 peptide product |
Heteromer P05067; Q9BYT8; | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| CryoEM structure of human presequence protease in partial closed state 1 |
Heteromer P05067; Q5JRX3; | |||||
| Assess | ||||||
| Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 35-42 |
Heteromer P05067; P12821; | 1×NAG; 1×NAG; 1×NAG; 1×ZN; 1×CL; 3×PEG; 1×PG4; 1×P6G; | ||||
| Assess | ||||||
| Atomic model of the Abeta D23N "Iowa" mutant using solid-state NMR, EM and Rosetta modeling | homo-27-mer | |||||
| Assess | ||||||
| Amyloid-beta 40 type 2 filament from the leptomeninges of individual with Alzheimer's disease and c… | homo-22-mer | |||||
| Assess | ||||||
| Type IIIb beta-amyloid 40 Filaments from Down Syndrome | homo-20-mer | |||||
| Assess | ||||||
| Structural Model for a 40-residue Beta-Amyloid Fibril with Three-Fold Symmetry, Positive Stagger | homo-18-mer | |||||
| Assess | ||||||
| Atomic Resolution Structure of Monomorphic AB42 Amyloid Fibrils | homo-18-mer | |||||
| Assess | ||||||
| Structural Model for a 40-residue Beta-Amyloid Fibril with Three-Fold Symmetry, Negative Stagger | homo-18-mer | |||||
| Assess | ||||||
| Mixing Abeta(1-40) and Abeta(1-42) peptides generates unique amyloid fibrils | homo-16-mer | |||||
| Assess | ||||||
| Mixing Abeta(1-40) and Abeta(1-42) peptides generates unique amyloid fibrils | homo-16-mer | |||||
| Assess | ||||||
| A New Structural Model of Abeta(1-40) Fibrils | homo-16-mer | |||||
| Assess | ||||||
| Abeta fibril (Morphology I) | homo-12-mer | |||||
| Assess | ||||||
| 42-Residue Beta Amyloid Fibril | homo-12-mer | |||||
| Assess | ||||||
| Structural Model for a 40-Residue Beta-Amyloid Fibril with Two-Fold Symmetry, Positive Stagger | homo-12-mer | |||||
| Assess | ||||||
| Structural Model for a 40-Residue Beta-Amyloid Fibril with Two-Fold Symmetry, Negative Stagger | homo-12-mer | |||||
| Assess | ||||||
| Amyloid-beta tetrameric filaments with the Arctic mutation (E22G) from Alzheimer's disease brains |… | homo-12-mer | |||||
| Assess | ||||||
| Covalently stabilized triangular trimer composed of Abeta17-36 beta-hairpins | homo-12-mer | |||||
| Assess | ||||||
| Triangular trimer of beta-hairpins derived from Abeta17-36 with an F20Cha mutation | homo-12-mer | |||||
| Assess | ||||||
| X-ray crystallographic structure of an A-beta 17_36 beta-hairpin. X-ray diffractometer data set. (L… | homo-12-mer | 2×JEF; | ||||
| Assess | ||||||
| X-ray crystallographic structure of an Abeta 17-36 beta-hairpin. LV(PHI)FAEDCGSNKCAII(SAR)L(ORN)V | homo-12-mer | |||||
| Assess | ||||||
| Amyloid Beta KLVFFAENVGS 16-26 D23N Iowa mutation | homo-12-mer | |||||
| Assess | ||||||
| Structure of an amyloid forming peptide GAIIGL (29-34) from amyloid beta | homo-12-mer | |||||
| Assess | ||||||
| Structure of an amyloid forming peptide KLVFFA from amyloid beta, alternate polymorph II | homo-12-mer | |||||
| Assess | ||||||
| S8 phosphorylated beta amyloid 40 fibrils | homo-10-mer | 10×2PO; | ||||
| Assess | ||||||
| Atomic-resolution 3D structure of amyloid-beta fibrils: the Osaka mutation | homo-10-mer | |||||
| Assess | ||||||
| Sarkosyl-extracted AppNL-G-F Abeta42 fibril structure | homo-10-mer | |||||
| Assess | ||||||
| Amyloid-beta (1-40) fibrils derived from a CAA patient | homo-10-mer | |||||
| Assess | ||||||
| Sarkosyl-extracted AppNL-G-F Abeta42 fibril structure (Methoxy-X04-labelled mice) | homo-10-mer | |||||
| Assess | ||||||
| DI1 Abeta fibril from tg-SwDI mouse | homo-10-mer | |||||
| Assess | ||||||
| Type I beta-amyloid 42 Filaments from Human Brain | homo-10-mer | 10×UNX; | ||||
| Assess | ||||||
| Type I beta-amyloid 42 Filaments from Down syndrome | homo-10-mer | |||||
| Assess | ||||||
| Murine type III Abeta fibril from APP/PS1 mouse | homo-10-mer | |||||
| Assess | ||||||
| MurineArc type I Abeta fibril from tg-APPArcSwe mouse | homo-10-mer | |||||
| Assess | ||||||
| Type IIIa beta-amyloid 40 Filaments from Down syndrome | homo-10-mer | |||||
| Assess | ||||||
| Murine type II Abeta fibril from ARTE10 mouse | homo-10-mer | |||||
| Assess | ||||||
| Murine type III Abeta fibril from ARTE10 mouse | homo-10-mer | |||||
| Assess | ||||||
| Murine type II Abeta fibril from APP23 mouse | homo-10-mer | |||||
| Assess | ||||||
| Murine type II Abeta fibril from tgAPPSwe mouse | homo-10-mer | |||||
| Assess | ||||||
| Type II beta-amyloid 42 Filaments from Human Brain | homo-10-mer | 10×UNX; | ||||
| Assess | ||||||
| Amyloid-Beta (20-34) with L-isoaspartate 23 | homo-10-mer | |||||
| Assess | ||||||
| VGSNKGAIIGL from Amyloid Beta determined by MicroED | homo-10-mer | |||||
| Assess | ||||||
| Near-atomic resolution fibril structure of complete amyloid-beta(1-42) by cryo-EM | homo-9-mer | |||||
| Assess | ||||||
| 40-residue beta-amyloid fibril derived from Alzheimer's disease brain | homo-9-mer | |||||
| Assess | ||||||
| Brain-derived 42-residue amyloid-beta fibril type B | homo-8-mer | |||||
| Assess | ||||||
| Brain-derived 42-residue amyloid-beta fibril type A | homo-8-mer | |||||
| Assess | ||||||
| Amyloid-beta assemblage on GM1-containing membranes | homo-8-mer | |||||
| Assess | ||||||
| 40-residue D23N beta amyloid fibril | homo-8-mer | |||||
| Assess | ||||||
| X-ray crystallographic structure of a beta-hairpin peptide derived from amyloid beta 16-36 | homo-8-mer | 7×HEZ; | ||||
| Assess | ||||||
| Structure of amyloid-beta derived peptide - NKGAIF | homo-8-mer | 8×PO4; | ||||
| Assess | ||||||
| Amyloid beta oligomer displayed on the alpha hemolysin scaffold | homo-7-mer | |||||
| Assess | ||||||
| Atomic resolution structure of a disease-relevant Abeta(1-42) amyloid fibril | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of the fibril formed by disaccharide-modified amyloid-beta(1-42) | homo-6-mer | 6×X6X; 6×ACY; | ||||
| Assess | ||||||
| Type I amyloid-beta 42 filaments from high-spin supernatants of aqueous extracts from Alzheimer's d… | homo-6-mer | |||||
| Assess | ||||||
| Amyloid-beta(1-40) fibril derived from Alzheimer's disease cortical tissue | homo-6-mer | |||||
| Assess | ||||||
| Ab typeII filament from Guam ALS/PDC | homo-6-mer | |||||
| Assess | ||||||
| Amyloid-beta 42 filaments extracted from the human brain with Arctic mutation (E22G) of Alzheimer's… | homo-6-mer | |||||
| Assess | ||||||
| Type II amyloid-beta 42 filaments from high-spin supernatants of aqueous extracts from Alzheimer's … | homo-6-mer | |||||
| Assess | ||||||
| Amyloid-beta (1-40) fibrils derived from familial Dutch-type CAA patient (population B) | homo-6-mer | |||||
| Assess | ||||||
| Racemic mixture of amyloid beta segment 35-MVGGVV-40 forms heterochiral rippled beta-sheet, include… | homo-6-mer | 6×YWK; | ||||
| Assess | ||||||
| Structure of an amyloid forming peptide NKGAII (residues 27-32) from amyloid beta | homo-6-mer | |||||
| Assess | ||||||
| Racemic mixture of amyloid beta segment 16-KLVFFA-21 forms heterochiral rippled beta-sheet | homo-6-mer | 6×TFA; | ||||
| Assess | ||||||
| DI2 Abeta fibril from tg-SwDI mouse | homo-5-mer | |||||
| Assess | ||||||
| DI3 Abeta fibril from tg-SwDI mouse | homo-5-mer | |||||
| Assess | ||||||
| 3D Structure of Alzheimer's Abeta(1-42) fibrils | homo-5-mer | |||||
| Assess | ||||||
| Amyloid-Beta (20-34) wild type | homo-5-mer | |||||
| Assess | ||||||
| Structure of pore-forming amyloid-beta tetramers | homo-4-mer | |||||
| Assess | ||||||
| Structure of segment MVGGVVIA from the amyloid-beta peptide (Ab, residues 35-42), alternate polymor… | homo-4-mer | |||||
| Assess | ||||||
| Structure of an amyloid forming peptide KLVFFA from amyloid beta in complex with orange G | homo-4-mer | 2×ORA; | ||||
| Assess | ||||||
| Structure of segment AIIGLM from the amyloid-beta peptide (Ab, residues 30-35) | homo-4-mer | |||||
| Assess | ||||||
| X-ray crystallographic structure of an A-beta 17_36 beta-hairpin. Synchrotron data set. (LVFFAEDCGS… | homo-3-mer | |||||
| Assess | ||||||
| A receptor molecule | homo-2-mer | 1×SGN; 6×ZN; 1×CA; 3×GOL; 1×ACT; 3×SCN; 1×SO4; 1×MG; | ||||
| Assess | ||||||
| The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure Analysis of APP E2 domain | homo-2-mer | 2×OS; | ||||
| Assess | ||||||
| Structure of the Heparin-induced E1-Dimer of the Amyloid Precursor Protein (APP) | homo-2-mer | 2×BU4; 1×SO4; 1×ACT; | ||||
| Assess | ||||||
| X-RAY CRYSTAL STRUCTURE OF THE PROTEASE INHIBITOR DOMAIN OF ALZHEIMER'S AMYLOID BETA-PROTEIN PRECUR… | homo-2-mer | |||||
| Assess | ||||||
| Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment | homo-2-mer | |||||
| Assess | ||||||
| X-ray crystallographic structure of a beta-hairpin peptide derived from amyloid beta 14-40 | homo-2-mer | 1×CL; | ||||
| Assess | ||||||
| Solution NMR structure of transmembrane domain of amyloid precursor protein V44M | homo-2-mer | |||||
| Assess | ||||||
| Solution NMR structure of transmembrane domain of amyloid precursor protein WT | homo-2-mer | |||||
| Assess | ||||||
| Electron cryo-microscopy of an Abeta(1-42)amyloid fibril | homo-2-mer | |||||
| Assess | ||||||
| Beta hairpin derived from Abeta17-36 with an F20Cha mutation | homo-2-mer | 2×CL; 1×NA; | ||||
| Assess | ||||||
| Zinc induced dimer of the metal binding domain 1-16 of human amyloid beta-peptide with Alzheimer's … | homo-2-mer | 1×ZN; | ||||
| Assess | ||||||
| Zinc bound dimer of the fragment of human amyloid-beta peptide with Alzheimer's disease pathogenic … | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Structure of segment MVGGVVIA from the amyloid-beta peptide (Ab, residues 35-42), alternate polymor… | homo-2-mer | |||||
| Assess | ||||||
| X-ray structure of the E2 domain of the human amyloid precursor protein (APP) in complex with copper | monomer | 1×ACT; 2×CU; 7×CD; | ||||
| Assess | ||||||
| X-ray structure of the E2 domain of the human amyloid precursor protein (APP) in complex with zinc | monomer | 1×ACT; 1×ZN; 8×CD; | ||||
| Assess | ||||||
| X-ray structure of the E2 domain of the human amyloid precursor protein (APP) in complex with cadmi… | monomer | 2×ACT; 9×CD; | ||||
| Assess | ||||||
| HIGH-RESOLUTION CRYSTAL STRUCTURE OF THE E1-DOMAIN of THE AMYLOID PRECURSOR PROTEIN | monomer | |||||
| Assess | ||||||
| Solution structure of CAPPD*, an independently folded extracellular domain of human Amyloid-beta Pr… | monomer | |||||
| Assess | ||||||
| The longer crystal structure of the grow factor like domain from Beta amypoid precusor protein (APP… | monomer | |||||
| Assess | ||||||
| Crystal structure of the N-terminal, growth factor-like domain of the amyloid precursor protein bou… | monomer | 1×CU; 1×GOL; | ||||
| Assess | ||||||
| N-TERMINAL DOMAIN OF THE AMYLOID PRECURSOR PROTEIN | monomer | |||||
| Assess | ||||||
| Structure of the Alzheimer's disease amyloid precursor protein copper binding domain | monomer | |||||
| Assess | ||||||
| Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain (Residues 126- 1… | monomer | |||||
| Assess | ||||||
| Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'small unit c… | monomer | 1×GOL; | ||||
| Assess | ||||||
| Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'small unit c… | monomer | 1×CU; | ||||
| Assess | ||||||
| Structure of the Alzheimer's Amyloid Precursor Protein (APP) copper binding domain (residues 133 to… | monomer | |||||
| Assess | ||||||
| Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'small unit c… | monomer | 1×CU1; | ||||
| Assess | ||||||
| Structure of the Alzheimer's Amyloid Precursor Protein (APP) Copper Binding Domain in 'large unit c… | monomer | 4×CU; | ||||
| Assess | ||||||
| Dynamic complex between all-D-enantiomeric peptide D3 with wild-type amyloid precursor protein 672-… | monomer | |||||
| Assess | ||||||
| Dynamic complex between all-D-enantiomeric peptide D3 with L723P mutant of amyloid precursor protei… | monomer | |||||
| Assess | ||||||
| The solution NMR structure of the transmembrane C-terminal domain of the amyloid precursor protein … | monomer | |||||
| Assess | ||||||
| Solution structure of the Alzheimer's disease amyloid beta-peptide (1-42) | monomer | |||||
| Assess | ||||||
| Aqueous Solution Structure of the Alzheimer's Disease Abeta Peptide (1-42) | monomer | |||||
| Assess | ||||||
| Solution structure of the amyloid beta-peptide (1-42) | monomer | |||||
| Assess | ||||||
| Structure of amyloid precursor protein's transmembrane domain | monomer | |||||
| Assess | ||||||
| THE SOLUTION STRUCTURE OF AMYLOID BETA-PEPTIDE (1-40) IN A WATER-MICELLE ENVIRONMENT. IS THE MEMBRA… | monomer | |||||
| Assess | ||||||
| SOLUTION STRUCTURE OF THE METHIONINE-OXIDIZED AMYLOID BETA-PEPTIDE (1-40). DOES OXIDATION AFFECT CO… | monomer | |||||
| Assess | ||||||
| THE ALZHEIMER`S DISEASE AMYLOID A4 PEPTIDE (RESIDUES 1-40) | monomer | |||||
| Assess | ||||||
| 3D NMR structure of a complex between the amyloid beta peptide (1-40) and the polyphenol epsilon-vi… | monomer | 2×23Y; | ||||
| Assess | ||||||
| A partially folded structure of amyloid-beta(1 40) in an aqueous environment | monomer | |||||
| Assess | ||||||
| 3D NMR structure of a complex between the amyloid beta peptide (1-40) and the polyphenol epsilon-vi… | monomer | 2×23Y; | ||||
| Assess | ||||||
| Amyloid-beta 40 type 1 filament from the leptomeninges of individual with Alzheimer's disease and c… | monomer | |||||
| Assess | ||||||
| Solution NMR Structure of APP G38L mutant TMD | monomer | |||||
| Assess | ||||||
| Solution NMR Structure of APP V44M mutant TMD | monomer | |||||
| Assess | ||||||
| Solution NMR Structure of APP G38P mutant TM | monomer | |||||
| Assess | ||||||
| Solution NMR Structure of APP I45T mutant TMD | monomer | |||||
| Assess | ||||||
| Solution NMR Structure of APP TMD | monomer | |||||
| Assess | ||||||
| SOLUTION NMR STRUCTURE OF AMYLOID BETA[E16], RESIDUES 1-28, 14 STRUCTURES | monomer | |||||
| Assess | ||||||
| SOLUTION STRUCTURE OF RESIDUES 1-28 OF THE AMYLOID BETA-PEPTIDE | monomer | |||||
| Assess | ||||||
| SOLUTION NMR STRUCTURE OF AMYLOID BETA[F16], RESIDUES 1-28, 15 STRUCTURES | monomer | |||||
| Assess | ||||||
| SOLUTION STRUCTURE OF RESIDUES 1-28 OF THE AMYLOID BETA-PEPTIDE | monomer | |||||
| Assess | ||||||
| ALZHEIMER'S DISEASE AMYLOID-BETA PEPTIDE (RESIDUES 10-35) | monomer | |||||
| Assess | ||||||
| Amyloid beta(18-41) peptide fusion with new antigen receptor variable domain from sharks | monomer | |||||
| Assess | ||||||
| Molecular structure of Cu(II)-bound amyloid-beta monomer implicated in inhibition of peptide self-a… | monomer | 1×CU; | ||||
| Assess | ||||||
| Molecular structure of Cu(II)-bound amyloid-beta monomer implicated in inhibition of peptide self-a… | monomer | 1×CU; | ||||
| Assess | ||||||
| NMR structure of the soluble A beta 17-34 peptide | monomer | |||||
| Assess | ||||||
| Zinc-binding domain of Alzheimer's disease amyloid beta-peptide complexed with a zinc (II) cation | monomer | 1×ZN; | ||||
| Assess | ||||||
| Zinc-binding domain of Alzheimer's disease amyloid beta-peptide in water solution at pH 6.5 | monomer | |||||
| Assess | ||||||
| Zinc-binding domain of Alzheimer's disease amyloid beta-peptide in TFE-water (80-20) solution | monomer | |||||
| Assess | ||||||
| NMR structure of the fragment 25-35 of beta amyloid peptide in 20/80 v:v hexafluoroisopropanol/wate… | monomer | |||||
| Assess | ||||||
| Solution structure of fragment (25-35) of beta amyloid peptide in SDS micellar solution | monomer | |||||
| Assess | ||||||
| NMR analysis of 25-35 fragment of beta amyloid peptide | monomer | |||||
| Assess | ||||||
| AMYLOID BETA PEPTIDE (25-35), NMR, 20 STRUCTURES | monomer | |||||
| Assess | ||||||
| Structure of segment KLVFFA from the amyloid-beta peptide (Ab, residues 16-21), alternate polymorph… | monomer | 1×ACT; | ||||
| Assess | ||||||
| Structure of segment KLVFFA from the amyloid-beta peptide (Ab, residues 16-21), alternate polymorph… | monomer | |||||
| Assess | ||||||
4 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7mrm.1.A | monomer | 0.74 | 93.57 | |||
| Assess | ||||||
| 6har.1.B | monomer | 0.62 | 90.57 | |||
| Assess | ||||||
| 5buo.1.A | monomer | 0.54 | 1×SGN; 3×ZN; 1×MG; | 100.00 | ||
| Assess | ||||||
| 2ysz.1.A | monomer | 0.53 | 84.21 | |||
| Assess | ||||||